CEO, Wren Therapeutics
Samuel Cohen, Ph.D is CEO of Wren Therapeutics, a biopharmaceutical company developing new treatments for protein misfolding diseases, such as Alzheimer’s and Parkinson’s diseases, based on more than a decade of research from its scientific founders. Dr Cohen is also currently the Entrepreneur-in-Residence at St John’s College, University of Cambridge. Dr Cohen was formerly an investment director at Malin plc and a consultant in the London office of Boston Consulting Group (BCG), where he advised leading healthcare and technology companies across Europe and the US. Dr Cohen previously spent a year as a Visiting Fellow at Harvard University and four years as a Research Fellow in Biophysical Chemistry at the Centre for Misfolding Diseases at the University of Cambridge. Dr Cohen’s scientific research focuses on neurodegenerative disorders and he is co-author of more than 30 scientific papers in leading journals. His research has been reported widely in the mainstream media, and his TED talk on Alzheimer’s disease has been viewed more than 2 million times.